Exploiting Real-Time Genomic Surveillance Data To Assess 4CMenB Meningococcal Vaccine Performance in Scotland, 2015 to 2022-Reference-Cited by-同舟云学术

Exploiting Real-Time Genomic Surveillance Data To Assess 4CMenB Meningococcal Vaccine Performance in Scotland, 2015 to 2022

Published:2023-04-25 Issue:2 Volume:14 Page:
ISSN:2150-7511
Container-title:mBio
language:en
Short-container-title:mBio

Author:

Rodrigues C. M. C.¹²³^ORCID,MacDonald L.⁴,Ure R.⁵,Smith A.⁵⁶,Cameron J. C.⁴,Maiden M. C. J.¹^ORCID

Affiliation:

1. Department of Biology, University of Oxford, Oxford, United Kingdom

2. Department of Infection Biology, London School of Hygiene and Tropical Medicine, London, United Kingdom

3. Department of Paediatrics, Imperial College Healthcare NHS Trust, London, United Kingdom

4. Public Health Scotland, Glasgow/Edinburgh, United Kingdom

5. Bacterial Respiratory Infection Service, Scottish Microbiology Reference Laboratory, Glasgow Royal Infirmary, Glasgow, United Kingdom

6. College of Medical, Veterinary & Life Sciences, Glasgow Dental Hospital & School, University of Glasgow, Glasgow, United Kingdom

Abstract

This study demonstrates the value of postimplementation genomic surveillance of vaccine-preventable pathogens in providing information on real-world vaccine performance. The data are consistent with 2 and 3 doses of Bexsero, delivered according to schedule, providing good protection against invasive disease caused by meningococci deduced from genomic data to be vaccine preventable.

Funder

Thrasher Research Fund

Wellcome Trust

Publisher

American Society for Microbiology

Subject

Virology,Microbiology

Link

https://journals.asm.org/doi/pdf/10.1128/mbio.00499-23

Reference30 articles.

1. Meningococcal carriage and disease—Population biology and evolution

2. Global incidence of serogroup B invasive meningococcal disease: a systematic review

3. Outcomes of invasive meningococcal serogroup B disease in children and adolescents (MOSAIC): a case-control study

4. A surveillance network for meningococcal disease in Europe

5. HUMAN IMMUNITY TO THE MENINGOCOCCUS